01965nam0 2200433 i 450 VAN010290920220209105255.451N978-1-4939-0742-720151014d2014 |0itac50 baengUS|||| |||||Clusters, orders, and trees: methods and applicationsin honor of Boris Mirkin's 70th birthdayFuad Aleskerov, Boris Goldengorin, Panos M. Pardalos editorsNew YorkSpringer2014XI, 404 p.ill.24 cm001VAN00671972001 Springer optimization and its applications210 Berlin [etc.]Springer2006-92VAN0239856Clusters, orders, and trees: methods and applications254438868-XXComputer science [MSC 2020]VANC019670MF90-XXOperations research, mathematical programming [MSC 2020]VANC025650MFArtificial IntelligenceKW:KData analysisKW:KMathematical programmingKW:KOperations ResearchKW:KTheory of computingKW:KTheory of dataKW:KUSNew YorkVANL000011AleskerovFuadVANV080334GoldengorinBorisVANV080335PardalosPanos M.VANV038535Springer <editore>VANV108073650Pardalos, P. M.Pardalos, Panos M.VANV063873ITSOL20240614RICAhttp://dx.doi.org/10.1007/978-1-4939-0742-7E-book – Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o ShibbolethBIBLIOTECA CENTRO DI SERVIZIO SBAVAN15NVAN0102909BIBLIOTECA CENTRO DI SERVIZIO SBA15CONS SBA EBOOK 4644 15EB 4644 20191106 Clusters, Orders, and Trees: Methods and Applications2544388UNICAMPANIA05893nam 2200433z- 450 991022004680332120210211(CKB)3800000000216309(oapen)https://directory.doabooks.org/handle/20.500.12854/50412(oapen)doab50412(EXLCZ)99380000000021630920202102d2017 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierIntellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and TreatmentFrontiers Media SA20171 online resource (179 p.)Frontiers Research Topics2-88945-045-7 Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer's disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90's and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer's disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout.Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer's disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90's and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer's disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout.Intellectual Disabilities in Down Syndrome from Birth and throughout LifeNeurosciencesbicsscAlzheimer's diseaseDown SyndromeGABAIntellectual DisabilitiesLanguageprenatalTreatmentNeurosciencesMarie-Claude Potierauth1190734Roger H. ReevesauthBOOK9910220046803321Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment3023978UNINA01441nam0 22003493i 450 MIL083114820251003044238.0978882040625720121115d2012 ||||0itac50 baitaitz01i xxxe z01nz01ncRDAcarrierAggregazioni pubbliche localiforme associative nel governo e nell'amministrazione tra autonomia politica, territorialità e governancePierpaolo ForteMilanoAngeli2012216 p.23 cmEconomia. Ricerche936La Collana Dases è confluita in Economia001CFI06392442001 Economia. Ricerche936Governo localeFIRLO1C805029I320.80945GOVERNO LOCALE. Italia23352.140945Amministrazione locale. Italia22Forte, PierpaoloRMGV008520290062ITIT-00000020121115IT-BN0095 NAP 01BCA Comprende monografie e periodici di diritto, testi di ingegneria, di scienze e tecnologia di nuova acquisizione. MIL0831148Biblioteca Centralizzata di Ateneo1 v. 01BCA SC. SOCIAL 543 01 0000076045 VMA A4 1 v.Y 2021111920211119 01Aggregazioni pubbliche locali837867UNISANNIO